[ad_1]
American Biofarmassutical Major Gillid Sciences has received approval from the United States Food and Drug Administration (US FDA) for its bi-annual HIV prevention injection, which can be marketed as ‘Yezatugo’.
Bloomberg reported that Gillid’s shares increased by about 3.5 percent-its biggest profit was about one month, and increased year-on-year (YOY) on 18 June, up to June 18, up to market close, Bloomberg said. The S&P 500 index increased better than the stock with an increase of 2 percent.
According to the AFP report, marketing under the brand name Yezto is marketed under the Lenkapavir, Yezto, has been shown to reduce the risk of HIV transmission more than 99.9 percent of adults and adolescents.
CEO of Gilliad says, ‘A way to eliminate HIV epidemic’
The HIV virus has been included by workers as the world’s “best tool”, especially since no vaccine is yet available, the drug is to be administered only twice a year and according to reports, compatible for a wide range of people.
Gilliad CEO Daniel O’De said in an email to Bloomberg, “This is a milestone in the decades-diligent battle against HIV. Now we have a way to end HIV epidemic.”
The BB report stated that the injection last year demonstrated “powerful ability” to remove HIV infection in two major international studies. The AFP reported that the results of the two tests were published in the New England Journal of Medicine, and Journal Science named Lenakpavir 2024 “years of success”.
Every year 1.3 million people are infected with HIV virus with the highest rate in Africa. Daily pills work, but can be forgotten by patients or stigma can also be applied as the bottle can reveal the health status of people.
What is the success rate of Yezatugo in tests?
An international study published in November 2024 has shown that the drug prevented all HIV cases between 2,180 men and transgender people – 96 percent lower than the level of background occurrence in that population.
And in June 2025, Gilid said that a test of shots in 2,000 women and adolescent girls in sub-Sahara Africa prevents 100 percent “unprecedented” of HIV cases.
It also improved the company’s old HIV prevention daily oral bullet Truewada in both studies.
Are there any side effects for Gillid’s Yezatugo?
Yes, there are some side effects. Bloomberg’s report said that about 1.2 percent of the people in the study reacted to the injection site and stopped taking the medicine.
According to the AFP report, other reported side effects include headache and nausea.
What is the cost of Yezatugo?
Gillid said that the price of Yeztoogo is $ 28,218 per year (around (nearby 24.50 lakhs), compared to your daily HIV prevention tablet, $ 26,400 list price of Deskovi. No specific value was given to India or other global markets.
The AFP report stated that the current list price of Lenkapavir for pre -approved use as a treatment for HIV is $ 39,000 annually.
Gillid spokesman Blair Bomwell told AFP via email, “We are working to make Yaztugo accessible to anyone, which it needs or wants to see and is expected to see comprehensive insurance coverage.”
Jab GSK-Arm will compete with the apretude prevention shot of the viiv healthcare, which is administered in an alternative months. This jab cost According to India’s data, 15,200 for 600mg/3ml vial.
In particular, the gilid already sells the same drug, the lencipavir, the price on the price as a treatment for people with multidrig-resistant HIV under the brand Sunlanka According to Indiamart, 23000/box for 300 mg tablet in India.
Where will the jab be available?
California-based company is looking at the drug to make the drug “best-sellers” in rich countries, but will also be rapidly pushed towards roll-out in poor and medium-income countries facing HIV crisis. And analysts surveyed by Bloomberg have expected the sales of Yezto more than $ 4 billion per year by 2031.
The report stated that Gillyad has already filed for approval in several countries, including Australia, Brazil, Canada, European Union, South Africa and all programs, for approval in many countries, which helps to speed up review of drugs used in developing countries.
Distribution to low -income countries affected by Donald Trump’s federal cuts?
The AFP reported that in October, Gillid signed agreements to produce and distribute general versions of drug in around 120 low income and medium -income countries with six pharma companies, which are pending regulatory approval, the AFP reported.
In a separate deal in December, Gillid announced a partnership with the United Nations Global Fund, AIDS Relief (PEPFAR) for the US President’s emergency plan, and others, to buy doses for two million people. However, Donald Trump’s deduction in the Pepfar program can now affect this development.
(Bloomberg, with input from AFP)
[ad_2]
